Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript
Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.61, expectations were $-0.85.
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$13.50 | 555,555 | 5,074,916 | 2024-02-12 | Filing | ||
$5.97 | 4,250 | Officer, Director | 1,049,068 | 2023-11-22 | Filing | |
$12.08 | 2,250 | Officer, Director | 1,044,818 | 2023-09-06 | Filing | |
$12.10 | 2,250 | Officer, Director | 1,042,568 | 2023-08-17 | Filing | |
$12.89 | 2,000 | Officer, Director | 1,040,318 | 2023-08-11 | Filing |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$12.81 | 76,182 | Officer | 0 | 2023-08-11 | Filing | |
$12.81 | 80,909 | Officer | 0 | 2023-08-11 | Filing | |
$13.16 | 74,625 | Officer | 0 | 2023-08-10 | Filing |